Six years ago, 63 percent of all new EU-approved medicines reached the Swedish market. Today the figure is 49 percent. Of the 168 medicines approved during the period 2021–2024, 82 are available in Sweden.
We see a negative trend, says Sofia Wallström, CEO of the pharmaceutical industry organization Lif.
According to Wallström, the main reason is that drug prices in Sweden are low, which means pharmaceutical manufacturers are investing more heavily in other markets.
We cannot have significantly lower prices than comparable countries, or the decline will continue.
Among the medicines that do not reach the Swedish market at all is a drug for ALS.
